ChromaDex receives orphan drug designation for Ataxia Telangiectasia cadidate

ChromaDex announced that the FDA granted orphan drug designation, or ODD, and rare pediatric disease, or RPD, designation for NRC, the company’s product candidate for the treatment of Ataxia Telangiectasia. Plans are underway to file an investigational new drug, or IND, application with the FDA in anticipation of conducting human clinical trials, which will be guided by Vilhelm Bohr, University of Copenhagen and Scientific Advisor to ChromaDex.